Exelixis | EXEL - Interest Income


Exelixis reported $16.13M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
Acadia Pharmaceuticals USD 8.33M 86K Dec/2025
Agios Pharmaceuticals USD 12.41M 959K Dec/2025
AstraZeneca USD 73M 62M Mar/2026
Bayer EUR 169M 39M Dec/2025
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Cytokinetics USD 11.02M 448K Mar/2026
Eisai JPY 3.11B 783M Mar/2024
Eli Lilly USD 65M 25M Sep/2025
Exelixis USD 16.13M 1.3M Mar/2026
Genmab DKK 25M 8M Jun/2025
Glaxosmithkline GBP 22M 4M Mar/2026
Incyte USD 33.69M 2.93M Mar/2026
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
MacroGenics USD 1.55M 26K Mar/2026
Merck USD 69M 27M Dec/2025
Moderna USD 70M 3M Dec/2025
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pfizer USD 115M 51M Mar/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Sanofi EUR 60M 54M Mar/2026
Takeda JPY 87.87B 43.48B Dec/2025
Ultragenyx Pharmaceutical USD 6.51M 649K Dec/2025
Xencor USD 6.2M 338K Dec/2025